Intercell Biomedical Ltd.

In 2004, Intercell acquired a manufacturing plant in Livingston, Scotland, which has enabled the Company to gain in‐house GMP manufacturing capabilities for its Japanese encephalitis vaccine and to manufacture the investigational product used in the Phase III clinical trials. With major investments in the last years, the Company has further increased capacities and established a state‐of the art, GMP commercial manufacturing facility to support the future supplies of its Japanese encephalitis vaccine. Besides the fully dedicated and further expandable manufacturing facility, the Livingston site has also separate development and clinical manufacturing capacities.